Could a common cholesterol drug ease ulcerative colitis?

NCT ID NCT05753267

Completed Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding fenofibrate, a drug typically used for high cholesterol, to the standard treatment mesalamine can improve symptoms and quality of life in people with mild-to-moderate ulcerative colitis. The trial enrolled 60 adults and measured changes in disease activity and inflammation markers. It is a small, early-stage study that explores a potential new use for an existing medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fenofibrate (a cholesterol-lowering drug) added to standard mesalamine
What this could lead to: If it works, this could point toward a new, affordable add-on treatment for mild-to-moderate ulcerative colitis that reduces inflammation.
What could go wrong: This is a small, completed trial with only 60 participants. The results may not apply to severe cases or to people on other medications, and fenofibrate's anti-inflammatory effect in the gut is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATORY BOWEL DISEASES

Contacts and locations

Locations

Tanta Unuversity

Tanta, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.